Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Current Medical Science

• Publication date

  2023-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11596-023-2789-3PMID 37752406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells

  2022cited by this paper
• A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders.

  2021cited by this paper
• Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer.

  2021influential reference
• Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2‐Hippo signaling pathway

  2021cited by this paper
• Control of the eIF4E activity: structural insights and pharmacological implications

  2021cited by this paper
• Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer

  2020cited by this paper
• eIF4E Overexpression Is Associated with Poor Prognoses of Ovarian Cancer

  2020cited by this paper
• p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer.

  2020cited by this paper
• Gastric cancer: a comprehensive review of current and future treatment strategies

  2020cited by this paper
• Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies

  2020cited by this paper
• Biochemical and Structural Insights into the Eukaryotic Translation Initiation Factor eIF4E.

  2019cited by this paper
• Hypermethylation of EIF4E promoter is associated with early onset of gastric cancer

  2018cited by this paper
• CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

  2018cited by this paper
• Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer.

  2018cited by this paper
• Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.

  2017cited by this paper
• Palbociclib‐induced autophagy and senescence in gastric cancer cells

  2017cited by this paper
• Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasis

  2016cited by this paper
• eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma

  2016influential reference
• Molecular classification of gastric cancer.

  2016cited by this paper
• peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas

  2016cited by this paper
• Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

  2016cited by this paper
• Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.

  2016influential reference
• Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.

  2015cited by this paper
• Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy

  2014cited by this paper
• The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance

  2014cited by this paper
• Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.

  2013cited by this paper
• Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer

  2011cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

  2010cited by this paper
• Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

  2009cited by this paper
• Targeting the eukaryotic translation initiation factor 4E for cancer therapy.

  2008cited by this paper
• Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors.

  2007cited by this paper
• Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

  2004cited by this paper
• Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome

  2004cited by this paper
• Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

  1997cited by this paper

• The Proteins Diversity of the eIF4E Family in the eIF4F Complex

  2025cites this paper
• Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward

  2025cites this paper
• Targeting senescent cells to reshape the tumor microenvironment and improve anticancer efficacy.

  2024cites this paper
• eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production

  2024cites this paper